Allen Bond

Neuromodulation : Global Product Intelligence Industry Analysis 2022

Press Release   •   Nov 13, 2017 12:30 IST

Infinium Global Research has added a new report on Global Neuromodulation Market. The report predicts the market size of Neuromodulation is expected to reach XX billion by 2022.

The market for global neuromodulation devices was valued at around USD 3.5 billion in 2015 and is expected to reach USD 6.5 billion by 2022, growing at a CAGR of around 9.3% during the forecast period of 2016 to 2022. Neuromodulation includes treatments that involve stimulation or administration of medications directly to the body’s nervous system for therapeutic purposes. The target cells for stimulation include nerves in the central and peripheral nervous systems, the autonomic nervous system, and the deep cell nuclei of the brain, resulting in modulation of their activity. Neuromodulation includes several modalities, and is a cross-disciplinary approach to pain control and neurologic dysfunction. Neuromodulation can be used to treat movement disorders, spasticity, and epilepsy, as well as pain syndromes. Devices are implanted which can either include drug delivery pumps or neural stimulators.

Get a Sample Report @

The most common type is spinal cord stimulation, which is used for back or lower extremity pain. Spinal cord stimulation involves electrical stimulation of the spinal cord to interrupt pain signals from the spinal cord to the brain, and to trade a painful sensation with a more pleasant tingling sensation. The technology has been present since the 1960s and in the past decade has become highly effective in the treatment of pain. In addition to chronic pain relief, other neuromodulation treatments now used include deep brain stimulation for essential tremor, Parkinson’s disease, dystonia, epilepsy and disorders such as depression, obsessive compulsive disorder and Tourette syndrome; sacral nerve stimulation for pelvic disorders and incontinence; gastric and colonic stimulation for gastrointestinal disorders such as dysmotility or obesity; vagus nerve stimulation for epilepsy, obesity or depression; carotid artery stimulation for hypertension; and spinal cord stimulation for ischemic disease such as angina and peripheral vascular disease.

Company profiles

Medtronic plc
Boston Scientific Corporation
St. Jude Medical
Cochlear Ltd.
Advanced Bionics
Sonova Group
Nevro Corporation
Neuronetics, Inc.

Make an Enquiry @

Key topics covered:

1.Scope of the report

2 Executive summary
3 Qualitative analysis

4 Global neuromodulation market, by technology, 2015 – 2022

5 Global neuromodulation market, by application, 2015 – 2022

6 Global neuromodulation market, by geography, 2015 – 2022

7 Company profiles

Click to View Complete Report @